Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers

Launched by SOCIEDAD DE LUCHA CONTRA EL CÁNCER DEL ECUADOR · Apr 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how the body’s chemicals, called metabolites, change in patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma before, during, and after their treatment. By analyzing these metabolites using advanced technology, researchers hope to identify helpful markers that can guide doctors in diagnosing and predicting how well patients will respond to treatment. This information could improve care for patients with these types of lymphoma.

To participate in this study, individuals must be 18 years or older, have a confirmed diagnosis of diffuse large B-cell lymphoma or high-grade B-cell lymphoma, and plan to receive full-dose treatment that includes specific chemotherapy drugs. Participants will undergo testing and provide blood samples at different stages of their treatment. It’s important to note that people with certain health conditions, like severe diabetes or active infections, may not be eligible for this trial. Overall, this study aims to enhance our understanding of these cancers and ultimately improve patient outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years and older;
• • Both sexes;
• • Patients with confirmed histopathological diagnosis of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma;
• • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2;
• • Patient intending to receive full-dose treatment (Monoclonal antibodies plus anthracycline based combination chemotherapy);
• • Staged with PET-CT or CT.
• Exclusion Criteria:
• • Patients with comorbidities that may interfere with the interpretation of the results (CKD in dialysis phase, Autoimmune diseases, uncontrolled Diabetes Mellitus (DM), symptomatic Heart Failure (CHF), HIV positive, positive serology for hepatitis B and C);
• • Patients requiring multiple blood transfusions (4 or more blood components for the same period or cause);
• • Pregnant women;
• • First-line treatment in another institution;
• • Diffuse transformed Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma